Results 171 to 180 of about 137,652 (287)

Personalized Treatment of Patients With Multiple Sclerosis: A Case Report and Literature Review

Medicine Bulletin, EarlyView.
ABSTRACT Managing multiple sclerosis (MS) with a highly active disease course presents significant challenges, particularly regarding the timing of therapeutic escalation and the preservation of brain volume. We present a personalized management strategy for a 36‐year‐old male with relapsing‐remitting MS (RRMS) who experienced initial misdiagnosis ...
Fengjun Wang, Han Wang, Yu Zhang, Guoxun Zhang   +3 more
wiley   +1 more source

Oral Corticosteroid Therapy in Lumbar Radiculopathy: Evidence From Randomized Controlled Trials. [PDF]

Cureus
Sharma V, Akil H, Badhe N, Abou Faour R, Nahle Z, Bhattacharyya M, Egu C, Najjar E.   +7 more
europepmc   +1 more source

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza, Elena Wolff, Michael Chou, Vera Bril, Hans Katzberg, Ahmed Bayoumi, Carolina Barnett‐Tapia   +6 more
wiley   +1 more source

Paradoxical pustular psoriasis following dupilumab therapy for bullous pemphigoid: A case report. [PDF]

JAAD Case Rep
Medina-Figueroa MD, Jiménez-Sacarello I, Sadurní-García M, Martín-García R, Santiago-Vázquez M.   +4 more
europepmc   +1 more source

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun, Diane Beauvais, Marlène Barnay, Marie‐Hélène Violleau, Stéphane Mathis, Fanny Duval, Guilhem Sole   +6 more
wiley   +1 more source

The efficacy and safety of iguratimod treatment in stable systemic lupus erythematosus: a preliminary prospective cohort study. [PDF]

Front Med (Lausanne)
Zhang L, Chen M, Shen B, Shen Z, Chu Y, Huang R.   +5 more
europepmc   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis. [PDF]

Front Immunol
Sun Y, Liu G, Zhang H, Ma K.
europepmc   +1 more source

Single‐center experience of the Crohn's disease exclusion diet in the United States: A retrospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield, Caroline Salozzo, Wenya Chen, Jennifer Strople, Jeffrey Brown, Joseph Runde   +5 more
wiley   +1 more source

A Rare Presentation of Mixed Warm and Cold Autoimmune Hemolytic Anemia. [PDF]

Case Rep Hematol
Anya O, Idenyi O, Chikere O, Shatzel JJ.
europepmc   +1 more source